SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway-Reference-Cited by-同舟云学术

SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway

Published:2018 Issue:54 Volume:8 Page:30919-30924
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Zhang Jinhang¹²³⁴⁵,Li Yanping¹²³⁴⁵,Liu Qinhui¹²³⁴⁵,Li Rui¹²³⁴⁵,Pu Shiyun¹²³⁴⁵,Yang Lina⁶⁷⁴⁵⁸,Feng Yanhuan⁶⁷⁴⁵⁸,Ma Liang⁶⁷⁴⁵⁸^ORCID

Affiliation:

1. Laboratory of Clinical Pharmacy and Adverse Drug Reaction

2. Department of Pharmacy

3. Collaborative Innovation Centre of Biotherapy

4. West China Hospital of Sichuan University

5. Chengdu 610041

6. Kidney Research Lab

7. Division of Nephrology

8. China

Abstract

NASH is characterized by hepatocellular injury accompanied by steatosis, inflammation and fibrosis. SKLB023 as a potent iNOS inhibitor, suppressed the activation of TGF-β/Smad signaling pathway by blocking iNOS expression to attenuate liver fibrosis in MCD diet-induced mice.

Funder

National Natural Science Foundation of China

Sichuan University

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/RA/C8RA04955F

Reference23 articles.

1. The global burden of liver disease: a challenge for methods and for public health

2. NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications